Sudden death of a case of hypertrophic obstructive cardiomyopathy 19 months after successful percutaneous transluminal septal myocardial ablation

Circulation Journal

Volumn 67, Issue 6, 2003, Pages 559-561

  Hirata, Kazuhito ^a   Wake, Minoru ^a   Asato, Hiroaki ^a   Kyushima, Masahiro ^a   Serizawa, Yoshimoto ^a  

^a Okinawa Prefectural Chubu Hospital   (Japan)

Author keywords

Hypertrophic obstructive cardiomyopathy; Nonsurgical septal reduction therapy; Percutaneous transluminal septal myocardial ablation

Indexed keywords

ATENOLOL; DISOPYRAMIDE; METOPROLOL; PILSICAINIDE; PROCAINAMIDE; PROPAFENONE;

ADULT; ARTICLE; AUTOPSY; CASE REPORT; CONGESTIVE HEART FAILURE; HEART ATRIUM FIBRILLATION; HEART MUSCLE FIBROSIS; HEART SURGERY; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE SEPTUM; HUMAN; HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY; MALE; PERCUTANEOUS TRANSLUMINAL SEPTAL MYOCARDIAL ABLATION; SUDDEN DEATH;

EID: 0038460062     PISSN: 13469843     EISSN: None     Source Type: Journal    
DOI: 10.1253/circj.67.559     Document Type: Article

References (15)

1. Knight C, Kurbaan AS, Seggewiss H, Henein M, Gunning M, Harrington D, et al. Nonsurgical septal reduction for hypertrophic obstructive cardiomyopathy: Outcome in the first series of patients. Circulation 1997; 95: 2075-2081.
2. Seggewiss H, Gleichmann U, Faber L, Fassbender D, Schmidt HK, Strick S. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: Acute results and 3-month follow-up in 25 patients. J Am Coil Cardiol 1998; 31: 259-264.
3. Flores-Ramirez R, Lakkis NM, Middleton KJ, Killip D, Spencer WH 3rd, Nagueh SF. Echocardiographic insights into the mechanisms of relief of left ventricular outflow tract obstruction after nonsurgical septal reduction therapy in patients with hypertrophic obstructive cardiomyopathy. J Am Coil Cardiol 2001; 37: 208-214.
4. Airoldi F, Di Mario C, Catanoso A, Dharmadhikari A, Tzifos V, Anzuini A, et al. Progressive decrease of outflow gradient and septum thickness after percutaneous alcoholization of the interventricular septum in hypertrophic obstructive cardiomyopathy. Ital Heart J 2000; 1: 200-206.
5. Henein MY, O'Sullivan CA, Ramzy IS, Sigwart U, Gibson DG. Electromechanical left ventricular behavior after nonsurgical septal reduction in patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 1999; 34: 1117-1122.
6. Mazur W, Nagueh SF, Lakkis NM, Middleton KJ, Killip D, Roberts R, et al. Regression of left ventricular hypertrophy after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. Circulation 2001; 20: 103: 1492-1496.
7. Nagueh SF, Lakkis NM, Middleton KJ, Killip D, Zoghbi WA, Quinones MA. Changes in left ventricular diastolic function 6 months after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. Circulation 1999; 99: 344-347.
8. Nagueh SF, Lakkis NM, Middleton KJ, Killip D, Zoghbi WA, Quinones MA. Changes in left ventricular filling and left atrial function six months after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 1999; 34: 1123-1128.
9. Inoue H, Waller BF, Zipes DP. Intracoronary ethyl alcohol or phenol injection ablates aconitine-induced ventricular tachycardia in dogs. J Am Coll Cardiol 1987; 10: 1342-1349.
10. Seggewiss H, Faber L, Gleichmann U. Percutaneous transluminal septal ablation in hypertrophic obstructive cardiomyopathy. Thorac Cardiovasc Surg 1999; 47: 94-100.
11. Okayama H, Sumitomo T, Morioka N, Yamamoto K, Kawada H. Usefulness of selective myocardial contrast echocardiography in percutaneous transluminal septal myocardial ablation: A case report. Jpn Circ J 2001; 65: 842-844.
12. Faber L, Meissner A, Ziemssen P, Seggewiss H. Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy: Long term follow up of the first series of 25 patients. Heart 2000; 83: 326-331.
13. Lakkis NM, Nagueh SF, Dunn JK, Killip D, Spencer WH 3rd. Nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy: One-year follow-up. J Am Coll Cardiol 2000; 36: 852-855.
14. Oomman A, Ramachandran P, Subramanyan K, Kalarickal MS, Osman MN. Percutaneous transluminal septal myocardial ablation in drug-resistant hypertrophic obstructive cardiomyopathy: 18-month follow-up results. J Invasive Cardiol 2001; 13: 526-530.
15. Wit AL, Dillon SM, Coromilas J. Anisotrophic reentry as a cause of ventricular tachyarrhythmias in myocardial infarction. In: Zipes DP, Jalife J, editors. Cardiac electrophysiology: From cell to bedside. Philadelphia; Saunders; 1995: 511-526.